Thursday 16 October, 2025
Objectives: Intravenous busulfan is a corner stone in conditioning regimens for pediatric hematopoietic stem cell transplantation. It is administered daily…
Read morePoster: Drug/Disease Modelling - Oncology
Non-linear mixed-effects modeling to evaluate the pre-analytical stability of uracilemia in the context of dihydropyrimidine dehydrogenase deficiency testing.
Thursday 16 October, 2025
Objectives: Dihydropyrimidine dehydrogenase (DPD) deficiency testing is mandatory in France [1] and recommended by the European Medicines Agency before initiating…
Read moreDeveloping a head and neck cancer model to assess the effect of radiotherapy on tumour growth inhibition and regrowth
Thursday 16 October, 2025
Introduction: We have previously developed agent-based tumour models that successfully replicate and predict the effect of irradiation on tumour growth…
Read morePopulation pharmacokinetic model of sorafenib and application to a case report
Thursday 16 October, 2025
Introduction: High inter- (61-65%) and intra-individual (44-47%) variability in pharmacokinetics (PK) of sorafenib was observed during phase I studies, as…
Read moreElacestrant Population Pharmacokinetic and Exposure-Response Modelling Analyses to Support Elacestrant Dose Recommendations in Metastatic Breast Cancer (mBC) patients
Thursday 16 October, 2025
Objectives: Elacestrant is a selective estrogen receptor degrader (SERD) developed for the treatment of estrogen receptor-positive breast cancer. Preliminary safety…
Read moreDevelopment of a Target-Mediated Drug Disposition Model for the Prediction of Target Occupancy of MEN1112, an Anti Bst1/CD157 Humanized Antibody for the Treatment of Acute Myeloid Leukaemia
Thursday 16 October, 2025
Objectives: The pharmacokinetics of MEN1112, a humanized de-fucosylated monoclonal IgG1 antibody directed against human Bst1/CD157, has been described in relapsed/refractory…
Read morePKPD modelling of MEN1611 anti-tumor effect in xenograft models to predict efficacy threshold concentrations in HER2-positive advanced or metastatic breast cancer patient population
Thursday 16 October, 2025
Objectives: A translational pharmacokinetic-pharmacodynamic (PKPD) modelling approach has been applied to determine the minimum target concentration of MEN1611, a novel…
Read moreQuantitative evaluation of the impact of CYP2D6 genetic polymorphisms on pharmacokinetics of tamoxifen and its metabolites in breast cancer patients
Thursday 16 October, 2025
Objectives: To develop a population pharmacokinetic (PopPK) model describing the disposition of tamoxifen (TAM) and three of its metabolites in…
Read morePopulation pharmacokinetic analysis of tamoxifen and its six metabolites in breast cancer patients: Quantification of the impact of genetic polymorphisms and co-medications on tamoxifen metabolism
Thursday 16 October, 2025
Objectives: Plasma levels of endoxifen (ENDO), the major active metabolite of tamoxifen (TAM), vary widely among individuals (1) which may…
Read moreOptimisation of the dose and schedule of everolimus and sorafenib combination therapy in patients with solid tumors using a PKPD/time-to-event model
Thursday 16 October, 2025
Objectives: Everolimus (EVE) and sorafenib (SOR) are oral targeted anti-cancer therapies blocking PI3K-AKT-mTOR and RAS-RAF-ERK (MAPK) pathways, respectively, and are currently…
Read more